Personalized Gene Therapy Treatment Market Report 2026

Personalized Gene Therapy Treatment Market Overview

• Personalized Gene Therapy Treatment market size has reached to $8.38 billion in 2025 • Expected to grow to $21.23 billion in 2030 at a compound annual growth rate (CAGR) of 20.4% • Growth Driver: The Rising Prevalence Of Genetic Disorders Is Fueling The Growth Of The Market Due To Increasing Cases That Require Targeted, Gene-Based Therapies • Market Trend: Strategic Partnerships Accelerating Personalized Gene Therapy Innovations • North America was the largest region in 2025.

What Is Covered Under Personalized Gene Therapy Treatment Market?

Personalized gene therapy treatment refers to professional medical treatment that delivers targeted therapies tailored to an individual’s unique genetic profile. It modifies, repairs, or replaces faulty genes to directly address underlying genetic conditions. Personalized gene therapy treatment enhances treatment precision, minimizes adverse effects, and improves therapeutic effectiveness. The main types of personalized gene therapy treatments are targeted treatments and pharmacogenomics. Targeted treatments are therapies designed to precisely modify or regulate specific genes associated with a disease to achieve maximum therapeutic effect with minimal side effects. The vector types are viral and non-viral and are distributed through several distribution channels, including hospitals, clinics, home administration, and others, for various applications across multiple medical fields, such as oncology, neurology, hematology, infectious diseases, ophthalmology, and others.

What Is The Personalized Gene Therapy Treatment Market Growth Forecast?

The personalized gene therapy treatment market size is expected to see exponential growth in the next few years. It will grow to $21.23 billion in 2030 at a compound annual growth rate (CAGR) of 20.4%. The growth in the forecast period can be attributed to increasing regulatory approvals for personalized gene therapies, rising demand for customized oncology treatments, expansion of gene therapy manufacturing capabilities, growing integration of AI in therapy design, increasing adoption of pharmacogenomics-guided treatments. Major trends in the forecast period include increasing adoption of gene editing-based therapies, rising use of personalized treatment protocols, growing integration of companion diagnostics, expansion of viral and non-viral vector platforms, enhanced focus on precision oncology applications.

Global Personalized Gene Therapy Treatment Market Segmentation

1) By Therapy: Targeted Treatments, Pharmacogenomics 2) By Vector Type: Viral, Non-Viral 3) By Distribution Channel: Hospitals, Clinics, Home Administration, Other Distribution Channels 4) By Application: Oncology, Neurology, Hematological, Infectious Diseases, Ophthalmology, Other Applications Subsegments: 1) By Targeted Treatments: Monoclonal Antibodies, Chimeric Antigen Receptor T-Cell Therapy (CAR-T), Small Interfering RNA (siRNA) Therapy, Antisense Oligonucleotides (ASO), Gene Editing Therapy 2) By Pharmacogenomics: Companion Diagnostics, Drug Metabolism Enzyme Testing, Genetic Biomarker Analysis, Single Nucleotide Polymorphism (SNP) Profiling, Adverse Drug Reaction (ADR) Prediction

What Is The Driver Of The Personalized Gene Therapy Treatment Market?

The growing prevalence of genetic disorders is expected to propel the growth of the personalized gene therapy treatment market going forward. Genetic disorders are conditions resulting from DNA abnormalities that disrupt normal body functions. The prevalence of genetic disorders is rising due to increasing parental age, as older reproductive cells have a higher risk of mutations that can be passed to offspring. Personalized gene therapy addresses genetic disorders by precisely correcting the defective genes responsible for the condition and tailors treatment to an individual’s genetic makeup, enhancing efficacy and reducing side effects. For instance, in October 2024, according to Cystic Fibrosis Trust, a UK-based charity dedicated to supporting people with cystic fibrosis, in 2022, around 11,148 cystic fibrosis (a genetic disorder) patients were registered, and this number grew to 11,318 in 2023, reflecting a 1.5% increase in patient registrations year over year Therefore, the growing prevalence of genetic disorders is driving the growth of the personalized gene therapy treatment industry.

Key Players In The Global Personalized Gene Therapy Treatment Market

Major companies operating in the personalized gene therapy treatment market are Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., BGI Genomics Co. Ltd., Invitae Corporation, Guardant Health Inc., GeneDx LLC, Ancestry Inc., Oxford Nanopore Technologies plc, Genomic Health Inc., 23andMe Holding Co., Color Health Inc., Helix OpCo LLC, Personalis Inc., Dante Genomics, Gene By Gene Ltd., Veritas Genetics Inc., Futura Genetics, Nebula Genomics Inc., Pathway Genomics Corporation

Global Personalized Gene Therapy Treatment Market Trends and Insights

Major companies operating in the personalized gene therapy treatment market are focusing on adopting strategic partnerships to expand technological capabilities and bring innovative therapies to patients more efficiently. Strategic partnerships are collaborative alliances between organizations to leverage each other’s strengths and resources for mutual growth and competitive advantage while sharing risks and benefits. For instance, in May 2025, Aldevron, a US-based company involved in the production of DNA, RNA, and protein, collaborated with Integrated DNA Technologies, a US-based provider of genomics solutions, to manufacture the world’s first mRNA-based personalized CRISPR therapy to treat an infant with a rare and life-threatening genetic condition, urea cycle disorder (UCD). This N of 1 therapy was developed and delivered in just six months by creating a custom guide RNA, an mRNA-encoded base editor, off-target safety services, and a clinically validated lipid nanoparticle delivery system. The therapy's development marks a significant milestone in personalized in vivo base-editing treatments.

What Are Latest Mergers And Acquisitions In The Personalized Gene Therapy Treatment Market?

In July 2025, Eli Lilly and Company, a US-based pharmaceutical company, acquired Verve Therapeutics, Inc. for $1.3 billion. With this acquisition, Eli Lilly aims to expand its portfolio into cardiovascular gene-editing therapies and strengthen its presence in the personalized gene therapy industry. Verve Therapeutics is a US-based clinical-stage company developing one-time base-editing gene therapies specifically aimed at cardiovascular disease.

Regional Insights

North America was the largest region in the personalized gene therapy treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Personalized Gene Therapy Treatment Market?

The personalized gene therapy treatment market consists of revenues earned by entities by providing services such as genetic testing and diagnostics, personalized therapy design, gene editing treatments, viral and non-viral vector delivery, patient-specific cell therapies, and post-treatment monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The personalized gene therapy treatment market also includes sales of viral vectors, gene editing platforms, cell culture systems, bioprocessing tools, and monitoring software. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Personalized Gene Therapy Treatment Market Report 2026?

The personalized gene therapy treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the personalized gene therapy treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.